Camphane chlorobenzamide
What is it?
An experimental camphane-based structural analogue of Chlodantane. The cage framework differs from adamantane; this is a chemical candidate, not an established treatment.
Research context
An experimental camphane-based structural analogue of Chlodantane. The cage framework differs from adamantane; this is a chemical candidate, not an established treatment.
What the studies found
animal · 2023
Mouse pharmacology experiments
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% at the reported 14-day assessment. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
Limit: Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes ↗analytical · 2019
Chemical synthesis and characterization; background pharmacology citations
The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.
Limit: Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes ↗Selected findings, not a systematic review or a treatment recommendation. Combination and related-preparation results cannot be attributed to this compound alone. See each source for access status and remaining limitations.
- Working classification
- Experimental adamantane / analogue
- Research collection
- Actoprotection & occupational pharmacology · editorial grouping
- Institutional provenance
- Not established for this compound record
- Last evidence review
- Full evidence review pending; source-check scope appears with each publication below.
What do we know?
- Human research
- —No human efficacy findings verified in this update
- Study methods
- —Source-specific animal, chemistry, patent or dissertation evidence
- Independent replication
- —Independent replication not established; translations are not separate experiments
- Source access
- —Access and review depth appear with each linked record
- Safety evidence
- —Human safety and interactions not established; animal activity is not a safe-use recommendation
These are independent review fields, not a rating. Missing evidence in this starter does not mean no research exists.
Chlodantane, Cyclontane and the ADK research programme ↗
Linked sources
Explore the research map and unresolved leads ↗
Comparative Evaluation of the Pharmacological Activity of Fatty Aromatic Amides and Amines with a Framework Moiety and Their Non-Covalent Complexes
A. A. Vernigora, R. V. Brunilin, O. V. Vostrikova, et al. · Pharmaceutical Chemistry Journal. 57(4):523–534
The camphane chlorobenzamide candidate increased treadmill performance by 23.22–25.20% at the reported 14-day assessment. Complexation of Chlodantane, Bromantane and ADK-918 neutralized their actoprotective effects in the tested preparations; the new derivatives were classified as moderately toxic.
- Population / setting
- Mouse pharmacology experiments
- What was checked
- Originating research institute’s publication record and abstract checked; full tables not reviewed.
Limitations & review scope
- Abstract-level animal findings do not establish human performance benefits or improved clinical safety.
- An effect at a 14-day assessment does not prove a benefit persisted for 14 days after one dose.
- The Russian and English versions are one publication, not independent replication.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.
Synthesis of New Camphane-Type Amides: Potential Synthetic Adaptogenes
I. A. Novakov, R. V. Brunilin, G. M. Butov, A. A. Vernigora, M. B. Navrotskii, A. S. Yablokov, S. N. Voloboev · Russian Journal of General Chemistry. 89(3):399–404
The study reports synthesis and characterization of camphane analogues and links their design to Chlodantane and related adamantanes. ADK-957 appears as a chlorophenoxyacetamide background lead; cited cold-protection activity is not a new clinical result in this chemistry paper.
- Population / setting
- Chemical synthesis and characterization; background pharmacology citations
- What was checked
- Author-uploaded paper’s accessible chemistry/background passages checked; earlier pharmacology not independently recovered.
Limitations & review scope
- Chemical characterization and a potential-adaptogen label do not demonstrate pharmacological efficacy.
- ADK-957’s original cold-exposure experiment and detailed safety data remain acquisition targets.
Source checked 2026-10-03. This is a source-linked record, not a completed evidence review.